Morgan Stanley analyst, Mark Purcell today upgraded GlaxoSmithKline’s rating to Equal Weight from Underweight. Purcell cut the stock’s target to EUR 1,665, from EUR 1,695 as he believes the company’s execution risks are better reflected in the lower valuation consideration.
STA Research has a consensus Strong Buy rating on the company’s stock. The current technical indicator is very bullish.
| AVG Analyst Rating | STA Analysis | |
|---|---|---|
Strong Buy
|
Bullish
|
|
Strong Buy
|
Neutral
|
|
|
Hold
|
Neutral
|
|
| N/A |
Very Bullish
|
|
Strong Buy
|
Slightly Bullish
|
|
Strong Buy
|
Slightly Bearish
|
|
Buy
|
Neutral
|
|
Hold
|
Neutral
|
|
Buy
|
Slightly Bullish
|
|
|
Strong Buy
|
Slightly Bullish
|
Do not have an account? Register here
